A team of Children’s Hospital of Pittsburgh of UPMC and University of Pittsburgh School of Medicine researchers including McGowan Institute for Regenerative Medicine
affiliated faculty members (pictured top to bottom) David H. Perlmutter, M.D., physician-in-chief and scientific director, Children’s Hospital, and Vira I. Heinz Professor and Chair of the Department of Pediatrics, Pitt School of Medicine, Simon C. Watkins, Ph.D., Professor, Department of Cell Biology and Physiology, University of Pittsburgh, and George Michalopoulos, M.D., Ph.D., Professor and Chairman of the Department of Pathology, Founder and Director of the Center for Biologic Imaging, University of Pittsburgh, found the liver scarring of α1-antitrypsin (AT) deficiency, the most common genetic cause for which children undergo liver transplantation, might be reversed or prevented with a medication that has long been used to treat seizures.
Because the anti-seizure drug is familiar to doctors and has a well-understood safety profile, clinical trials could begin immediately to see whether it can help patients with AT deficiency, said senior author Dr. Perlmutter.
In the classic form of the disease, which affects 1 in 3,000 live births, a gene mutation leads to an abnormal protein, dubbed ATZ, that unlike its normal counterpart is prone to aggregation.
“These aggregates of ATZ accumulate in the liver cells and eventually lead to scarring, or fibrosis, of the organ and set the stage for tumor development,” Dr. Perlmutter said. “The disease sometimes doesn’t show itself until adulthood, when the liver starts to fail due to cirrhosis or cancer.”
For the study, he and his colleagues treated an ATZ cell line with carbamazepine, or Tegretol. Although this drug has been used primarily to treat seizure disorders, some recent work has suggested that it could enhance a natural cellular pathway called autophagy, or self-digestion, and so the Pitt researchers reasoned that it might be able to rid the cells of the toxic aggregated ATZ.
They found that carbamazepine did, indeed, cause a marked decrease in ATZ because the abnormal proteins were degraded more quickly via autophagy, and so they did another experiment in a mouse model of AT deficiency.
“The amount of ATZ decreased in the livers of the mice treated with carbamazepine,” Dr. Perlmutter said. “The most amazing finding was that the drug reversed the fibrosis in the livers of the mice and, after 2 weeks of treatment, the liver tissue resembled that of a healthy mouse.”
The ability of carbamazepine and drugs like it to “soup up” the cell’s autophagy machinery might have value in other disorders ― such as Alzheimer’s disease, Huntington’s disease, and Parkinsonism ― that are thought to be caused by toxic effects of protein clumping in the brain. Dr. Perlmutter and his colleagues are now exploring these possibilities in preclinical studies.
Illustration: McGowan Institute for Regenerative Medicine.
Children’s Hospital of Pittsburgh of UPMC News Release (06/03/10)
Daily News and Analysis (06/04/10)
Bio: Dr. David Perlmutter
Bio: Dr. Simon Watkins
Bio: Dr. George Michalopoulos
Abstract (Science, Published online June 3, 2010.)